Gray-Zone Lymphoma — Trials

Gray-Zone Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

18 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 8
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: David Bond, MD
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00001337	Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma	completed	Phase 2	348	National Cancer Institute (NCI)NIH	1	Jun 22, 2025	clinicaltrials
NCT03255018	Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas	completed	Phase 2	12	National Cancer Institute (NCI)NIH	1	Nov 28, 2023